You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: April 26, 2024

Claims for Patent: 8,349,323

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 8,349,323

Title:	Cytokine antagonists for neurological and neuropsychiatric disorders
Abstract:	A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection.
Inventor(s):	Tobinick; Edward L. (Los Angeles, CA)
Assignee:	Tact IP, LLC (Highland Beach, FL)
Application Number:	13/400,244
Patent Claims:	1. A method for delivering a biologic pharmaceutical, comprising: administering an effective amount of a biologic pharmaceutical to a patient in need thereof by perispinal injection, without direct intrathecal or direct epidural injection. 2. The method of claim 1, wherein said biologic is a TNF antagonist. 3. The method of claim 2, wherein said biologic is a TNF antagonist selected from the group consisting of etanercept, infliximab, CDP571 (a humanized monoclonal anti-TNF -alpha IgG4 antibody), CD P 870 (a humanized monoclonal anti-TNF-alpha antibody fragment), D2E7 (a human anti-TNF mAb), soluble TNF receptor Type I, pegylated soluble TNF receptor Type I (PEGs TNF-R1) and onercept, a recombinant TNF binding protein (r-TBP-1). 4. The method of claim 2, wherein said biologic is D2E7 (a human anti-TNF mAb). 5. The method of claim 1, wherein said biologic is an interleukin-1 antagonist. 6. The method of claim 1, wherein said effective amount of a biologic is delivered to the cerebrospinal fluid of a human by perispinal injection without direct intrathecal or direct epidural injection.

Details for Patent 8,349,323

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Janssen Biotech, Inc.	REMICADE	infliximab	For Injection	103772	08/24/1998	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	11/02/1998	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	For Injection	103795	05/27/1999	⤷ Try a Trial	2019-02-24
Immunex Corporation	ENBREL	etanercept	Injection	103795	09/27/2004	⤷ Try a Trial	2019-02-24
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.